R&D/Clinical Trials

Alteogen grants Novartis options to develop subcutaneous formulations using its ALT-B4 hyaluronidase platform, NewBiologix and Synastra partner to develop a stable producer cell line, and RedHill acquires global commercialization rights to Ferring's Rebyota and Clenpiq.

GSK is advancing its mRNA seasonal influenza vaccine candidate FLUm3HA.b-3NA into a Phase III efficacy trial starting in September.

RBQM implementations fail not because the software is wrong — but because the human environment surrounding it was never engineered.

Eli Lilly has agreed to acquire Merida Biosciences for up to $2.875 billion to gain a precision autoantibody degradation platform led by MER511.

BioNTech and Genentech elect to end their Phase II trial of autogene Cevumeran after DSMB identified a numerical overall survival imbalance and recommended to terminate.

DualityBio has licensed its Dupac next-generation ADC payload platform to Genentech, and Teva has entered a stalking horse bid to acquire BioXcel's Igalmi.

Osivax and GC Biopharma agree to co-develop an influenza vaccine combining Osivax's OVX836 with GC Biopharma's GC FLU.

K2 Therapeutics CEO discusses China's biotech rise, the case for global asset acquisition, and what defines a successful biotech.

Beyond tau and TREM2: checkpoint inhibition, inflammasome drugs, brain delivery technologies, and biomarker-led diagnostics reshape Alzheimer's pipeline.

Biohaven grants SK Biopharmaceuticals an exclusive worldwide license to its Kv7 ion channel platform, while Haisco licenses a preclinical type 2 inflammatory disease asset to newly formed Sentivera.

Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk.

McKesson has agreed to acquire Precision Medicine Group for $2.25 billion, while Lundbeck has expanded its partnership with Eversana to scale AI-driven workflows.

Hanmi Pharm has licensed HM17321 to Genentech for up to $2.3 billion, including a $190 million upfront payment.

In the first part of a two-part series, Carre reviews of the tau and TREM2 approaches reshaping Alzheimer's drug development, with key findings from AAIC 2026 in London.

K2 Therapeutics CEO Ying Huang on how in-licensing assets with existing human data can cut years and billions from the drug development timeline.

From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million biosimilar collaboration — this week's deals and approvals reveal a lot about how pharmaceutical strategy is evolving.

K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech innovation surge irreversible.

Norstella’s VP of thought leadership discusses why pharma spent more on R&D, got fewer drugs, and is heading toward a $500 billion patent cliff unprepared.

LEO Pharma agrees to acquire dersimelagon, OmniAb signs a ion channel discovery collaboration with Eli Lilly, Chugai grants GSK an exclusive worldwide license to AID351, and BioMarin acquires Alesta Therapeutics to gain ALE1.

Henlius Biotech has granted Sandoz exclusive ex-China commercialization rights to up to 10 monoclonal antibody and ADC biosimilars for up to $322 million.

From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.

Rena Denoncourt, chief operating officer at Corsera Health, discusses the operational challenges of building a startup and how she balances prioritization with the flexibility drug development demands.

Dr. Nick Botwood, chief medical officer and head of research and development at Syndax Pharmaceuticals, draws on his career to explain what separates good R&D organizations from great ones.

Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.

BeOne Medicines and Revolution Medicines enter a two-part deal pairing BeOne's PRMT5 inhibitor and EGFR×MET trispecific antibody with Revolution's four clinical RAS(ON) inhibitors.